Key Takeaways DexCom received a warning letter from the Food and Drug Administration following inspections of two of its ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...

Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company ...

DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

A Form 483 is a type of agency report containing "observations" that FDA inspectors "deem to be objectionable." Dexcom manufactures its products at its headquarters in San Diego, California and at ...